United States
Semen analysis in the United States
What a semen analysis shows in US practice, which guideline applies, and why prices are not estimated.
- Published
- Modified
- Clinician review
- Not yet
Short answer
A semen analysis in the United States should still be a laboratory examination of volume, concentration, motility and morphology. Professional practice follows AUA/ASRM guidance and the WHO laboratory method. Who orders the test, what you pay, and whether a repeat is bundled are local. SemenBoost does not publish an unverified US price.
Key takeaways
- The reference limits on this site are the WHO figures, which AUA/ASRM materials also reflect after the 6th edition.
- Testosterone prescribed for symptoms can be the reason the analysis is abnormal.
- Coverage questions belong to your plan, not to a national average.
- No state or city page is generated without verified providers.
| Measurement | Reference value | How to read it |
|---|---|---|
| Semen volume | 1.4 ml or more | Within the current reference range at or above this value |
| Sperm concentration | 16 million/ml or more | Within the current reference range at or above this value |
| Total sperm number | 39 million or more | Within the current reference range at or above this value |
| Total motility | 42 % or more | Within the current reference range at or above this value |
| Progressive motility | 30 % or more | Within the current reference range at or above this value |
| Vitality | 54 % or more | Within the current reference range at or above this value |
| Normal morphology | 4 % or more | Within the current reference range at or above this value |
NICE also cites semen pH of 7.2 or more. These are lower reference limits, not a fertility diagnosis.
Who orders it
A primary-care clinician, a urologist or a fertility clinic can request it. Use a laboratory that states it follows the WHO manual. A result with no method, no abstinence interval and no time from collection to analysis is a weak result. Preparation is the same science in both countries. The administration is not.
Guideline context
AUA/ASRM recommends evaluating the male partner rather than assuming infertility is only a female-factor question. The guideline says not to prescribe exogenous testosterone when fertility is a current or future goal. If you are already on therapy, read TRT and fertility before the appointment so you can describe the product accurately.
After the result
An abnormal analysis is repeated and then interpreted with an examination. Very low or absent sperm needs a specialist, not a mail-order supplement. US testing and US clinics explain what this directory will and will not list.
Related
Sources
- Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline (amended 2024) — American Urological Association, 2024
- WHO laboratory manual for the examination and processing of human semen, 6th edition — World Health Organization, 2021
- Fertility problems: assessment and treatment (NG257) — NICE, 2026
- Assisted reproductive technology (ART) — Centers for Disease Control and Prevention
How this page was prepared
Drafted with automated research assistance and checked against the cited primary sources. A named clinician has not reviewed this page. Medical review is pending. Changes to reference values are not published automatically.